{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T01:28:14Z","timestamp":1778376494685,"version":"3.51.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>Thyroid dysfunction has been reported during Regorafenib (Reg) administration, but no detailed study is presently available.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Design<\/jats:title>\n<jats:p>Prospective, observational cohort study. Patients with documented metastatic colorectal cancer and progression of disease during or within 3 months after the last standard therapy, with no evidence and history of previous thyroid disease were enrolled.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Twenty-five consecutive patients were evaluated before and 8\u201350 weeks after initiating Reg therapy by monthly clinical, ultrasound and laboratory (thyrotropin (TSH), free thyroxine (fT4), antithyroglobulin (TgAb) and antithyroid peroxidase (TPOAb)) evaluation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Thirteen\/25 patients (52%) became hypothyroid (TSH: 12.5\u2009\u00b1\u20094.01\u2009IU\/L, range: 4.6\u201322.0) within 5 months of therapy. TPOAb became detectable (99\u2013155\u2009IU\/mL) in 2\/25 (8%) patients. Thyroid volume progressively decreased (from 8.6\u2009<jats:italic>\u00b1<\/jats:italic>\u20092.2\u2009mL to 4.9\u2009\u00b1\u20092.4\u2009mL after 5 months of Reg therapy, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). The progression-free survival (PFS) was longer in patients developing hypothyroidism (43 weeks) than in those remaining euthyroid (17 weeks, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Fatigue (the most common general serious Reg adverse event) was associated with hypothyroidism severity and reversed after levothyroxine therapy (L-T4).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Reg rapidly causes hypothyroidism in about 50% of patients and in a minority of them also triggers thyroid autoimmunity. Reg-induced hypothyroidism was strictly related to fatigue, easily reversed by L-T4 administration and associated to longer survival. These results suggest that prompt recognition of hypothyroidism in patients with severe fatigue may prevent unnecessary Reg dose reduction or withdrawal.<\/jats:p>\n<\/jats:sec>","DOI":"10.1530\/eje-17-0231","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:40:29Z","timestamp":1493858429000},"page":"85-92","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":22,"title":["Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?"],"prefix":"10.1093","volume":"177","author":[{"given":"Fabiana","family":"Pani","sequence":"first","affiliation":[{"name":"1Endocrinology Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Massidda","sequence":"additional","affiliation":[{"name":"1Endocrinology Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Pusceddu","sequence":"additional","affiliation":[{"name":"2Medical Oncology UnitDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Puzzoni","sequence":"additional","affiliation":[{"name":"2Medical Oncology UnitDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Massa","sequence":"additional","affiliation":[{"name":"2Medical Oncology UnitDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clelia","family":"Madeddu","sequence":"additional","affiliation":[{"name":"2Medical Oncology UnitDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[{"name":"2Medical Oncology UnitDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Mariotti","sequence":"additional","affiliation":[{"name":"1Endocrinology Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2017060217252181000_177.1.85.1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25864"},{"key":"2017060217252181000_177.1.85.2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/PPO.0000000000000192","article-title":"Targeting angiogenesis in colorectal cancer","volume":"22","author":"Kircher","year":"2016","journal-title":"Cancer Journal"},{"key":"2017060217252181000_177.1.85.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"2017060217252181000_177.1.85.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61857-1"},{"key":"2017060217252181000_177.1.85.5","first-page":"4059","article-title":"Investigation of regorafenib-induced hypothyroidism in patients with metastatic colorectal cancer","volume":"35","author":"Sugita","year":"2015","journal-title":"Anticancer Research"},{"key":"2017060217252181000_177.1.85.6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-S1-22"},{"key":"2017060217252181000_177.1.85.7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-S1-4"},{"key":"2017060217252181000_177.1.85.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.28715","article-title":"Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials","volume":"136","author":"Santoni","year":"2015","journal-title":"International Journal of Cancer"},{"key":"2017060217252181000_177.1.85.9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1089\/thy.2013.0241","article-title":"Thyroid dysfunction as an unintended side effect of anticancer drugs","volume":"11","author":"Torino","year":"2013","journal-title":"Thyroid"},{"key":"2017060217252181000_177.1.85.10","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"2017060217252181000_177.1.85.11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3892\/ol.2013.1424","article-title":"RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma","volume":"6","author":"Ruan","year":"2013","journal-title":"Oncology Letters"},{"key":"2017060217252181000_177.1.85.12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0028"},{"key":"2017060217252181000_177.1.85.13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2265.1988.tb03672.x","article-title":"The value of thyroid volume measured by ultrasonography in the diagnosis of goiter","volume":"28","author":"Berghout","year":"1988","journal-title":"Clinical Endocrinology"},{"key":"2017060217252181000_177.1.85.14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1530\/ERC-13-0201","article-title":"Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma","volume":"20","author":"Bianchi","year":"2013","journal-title":"Endocrine-Related Cancer"},{"key":"2017060217252181000_177.1.85.15","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/thy.2015.0170","article-title":"Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved?","volume":"11","author":"Pani","year":"2015","journal-title":"Thyroid"},{"key":"2017060217252181000_177.1.85.16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0456"},{"key":"2017060217252181000_177.1.85.17","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1089\/thy.2016.0159","article-title":"Hypothyroidism and thyroid autoimmunity as a prognostic biomarker of better response in metastatic cancer long-term survivors treated with sunitinib","volume":"9","author":"Pani","year":"2016","journal-title":"Thyroid"},{"key":"2017060217252181000_177.1.85.18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-14-0198","article-title":"Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors","volume":"171","author":"Illouz","year":"2014","journal-title":"European Journal of Endocrinology"},{"key":"2017060217252181000_177.1.85.19","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0414"},{"key":"2017060217252181000_177.1.85.20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1172"},{"key":"2017060217252181000_177.1.85.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03253.x"},{"key":"2017060217252181000_177.1.85.22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/annonc\/mdr275","article-title":"Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?","volume":"23","author":"Sabatier","year":"2014","journal-title":"Annals of Oncology"},{"key":"2017060217252181000_177.1.85.23","first-page":"3177","article-title":"Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy","volume":"34","author":"Kust","year":"2014","journal-title":"Anticancer Research"},{"key":"2017060217252181000_177.1.85.24","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, June 2010 NIC: General disorders and administration site conditions: 22."},{"key":"2017060217252181000_177.1.85.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70156-7"},{"key":"2017060217252181000_177.1.85.26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000382067","article-title":"Improving patient outcomes with regorafenib for metastatic colorectal cancer-patients selection, dosing, patient education, prophylaxis, and management of adverse events","volume":"38","author":"Hofheinz","year":"2015","journal-title":"Oncology Research and Treatment"},{"key":"2017060217252181000_177.1.85.27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4137\/CMO.S38335","article-title":"Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in French clinical practice","volume":"10","author":"Calcagno","year":"2016","journal-title":"Clinical Medicine Insights: Oncology"},{"key":"2017060217252181000_177.1.85.28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s12094-014-1212-8","article-title":"Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer","volume":"11","author":"Sastre","year":"2014","journal-title":"Clinical and Translational Oncology"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/177\/1\/85.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-17-0231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:10:44Z","timestamp":1676391044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/177\/1\/85\/6655353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":28,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eje-17-0231","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}